Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Golimumab/Guselkumab - Janssen Research & Development

Next Previous
Drug Profile

Golimumab/Guselkumab - Janssen Research & Development

Alternative Names: JNJ-4804; JNJ-4804 combination therapy; JNJ-78934804

Latest Information Update: 18 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Research & Development
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Monoclonal antibodies
  • Mechanism of Action Interleukin-23 subunit p19 inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Crohn's disease; Ulcerative colitis
  • Phase II Psoriatic arthritis

Most Recent Events

  • 23 May 2026 Phase-III clinical trials in Ulcerative colitis (Treatment-experienced) in Japan (SC) (NCT07577856)
  • 23 May 2026 Phase-III clinical trials in Ulcerative colitis (Treatment-experienced) in USA (SC) (NCT07577856)
  • 22 May 2026 Phase-III clinical trials in Crohn's disease (Treatment-experienced) in Japan (SC) (NCT07577843)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top